**PUBLIC HEALTH SERVICE**

**BIOLOGICAL MATERIALS LICENSE AGREEMENT**

This **Agreement** is based on the model Biological Material License Agreement adopted by the U.S. Public Health Service (“**PHS**”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“**NIH**”), the Centers for Disease Control and Prevention (“**CDC**”), and the Food and Drug Administration (“**FDA**”), which are agencies of the **PHS** within the Department of Health and Human Services (“**HHS**”).

This Cover Page identifies the Parties to this **Agreement**:

The U.S. Department of Health and Human Services, as represented by

[Insert the full name of the IC]

an Institute or Center (hereinafter referred to as the “**IC**”) of the

[INSERT as appropriate: NIH, CDC, or FDA]

and

[Insert Company’s official name],

hereinafter referred to as the “**Licensee**”,

having offices at [Insert Company’s address],

created and operating under the laws of [Insert State of Incorporation].

**Tax ID No.:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**L#:**

1. Definitions:
	1. “**Government**” means the government of the United States of America.
	2. “**FDA**” means the Food and Drug Administration.

 “**Materials**” means the following biological materials including all progeny, subclones, and unmodified derivatives thereof: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_, as described in \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ and developed in the laboratory of \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_at the **IC**.

**“Licensed Field of Use**” means \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_.

“**Licensed Products**” means \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_.

“**Net Sales**” means the total gross receipts by the **Licensee** for sales of **Licensed Products** or from income from leasing, renting, or otherwise making **Licensed Products** available to others without sale or other dispositions transferring title, whether invoiced or not, less returns and allowances, packing costs, insurance costs, freight out, taxes or excise duties imposed on the transaction (if separately invoiced), and wholesaler and cash discounts in amounts customary in the trade to the extent actually granted. No deductions shall be made for commissions paid to individuals, whether they are with independent sales agencies or regularly employed by the **Licensee**, or for the cost of collections.

1. The **Licensee** desires to obtain a license from the **IC** to use the **Materials** provided under this **Agreement** in its commercial research or product development and marketing activities. The **Licensee** represents that it has the facilities, personnel, and expertise to use the **Materials** or the **Licensed Products** for commercial purposes and agrees to expend reasonable efforts and resources to develop the **Materials** or the **Licensed Products** for commercial use or commercial research.
2. The **IC** hereby grants to the **Licensee**:

a worldwide, non-exclusive license to make, have made, and use the **Materials** or the **Licensed Products** in the **Licensed Field of Use**; and

a worldwide, non-exclusive license to sell and have sold, to offer to sell and to import the **Licensed Products** in the **Licensed** **Field of Use**.

1. In consideration of the grant in Paragraph 3, the **Licensee** hereby agrees to make the following payments to the **IC**:

Within sixty (60) days of its execution of this **Agreement**, a noncreditable, nonrefundable license issue royalty of \_\_\_\_\_\_\_\_\_\_ dollars ($X).

The first minimum annual royalty of \_\_\_\_\_\_\_\_\_\_ dollars ($XX) is due within sixty (60) days of the effective date of this **Agreement** and may be prorated according to the fraction of the calendar year remaining between the effective date of this **Agreement** and the next subsequent January 1;

Subsequent minimum annual royalty payments are due and payable on January 1 of each calendar year and may be credited against any earned royalties due for sales made in that year;

An earned royalty of \_\_\_\_\_\_\_\_\_\_\_\_\_\_ percent (X%) of **Net Sales**, which shall be due and payable within sixty (60) days of the end of each calendar year; and

All payments required under this **Agreement** shall be paid in U.S. dollars and payment options are listed in Appendix C. For conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York foreign exchange rate quoted in *The Wall Street Journal* on the day that the payment is due.

* + 1. Any loss of exchange, value, taxes, or other expenses incurred in the transfer or conversion to U.S. dollars shall be paid entirely by the **Licensee**; and
		2. Additional royalties may be assessed by the **IC** on any payment that is more than ninety (90) days overdue at the rate of one percent (1%) per month. This one percent (1%) per month rate may be applied retroactively from the original due date until the date of receipt by the **IC** of the overdue payment and additional royalties. The payment of any additional royalties shall not prevent the **IC** from exercising any other rights it may have as a consequence of the lateness of any payment.
1. Upon receipt by the **IC** of the license issue royalty and the prorated first year minimum annual royalty and verification of these royalties, the **IC** agrees to provide the **Licensee** with samples of the **Materials**, as available, and to replace these **Materials**, as available, at reasonable cost, in the event of their unintentional destruction. The **IC s**hall provide the **Materials** to the **Licensee** at the **Licensee’s** expense and as specified in Appendix A.
2. The **Licensee** agrees to make written reports to the **IC** within sixty (60) days of December 31 for each calendar year. This report shall state: the number, description, and aggregate **Net Sales** of **Licensed Products** made, sold, or otherwise disposed of; the total gross income received by the **Licensee** from leasing, renting, or otherwise making **Licensed Products** available to others without sale or other disposition transferring title, during the calendar year; and the resulting calculation of earned royalties due to the **IC** pursuant to Paragraph 4(d) and as shown in the example in Appendix B. The **Licensee** shall submit each report to the **IC** at the Mailing Address for **Agreement** notices indicated on the Signature Page.
3. The **Licensee** agrees to supply the laboratory of Dr. \_\_\_\_\_\_\_\_\_\_\_\_\_ at the **IC** at no charge, reasonable quantities of **Materials** or the **Licensed Products** that the **Licensee** makes, uses, sells, or offers for sale or otherwise makes available for public use. The **Licensee** also agrees to supply, to the Mailing Address for **Agreement** notices indicated on the Signature Page, the Office of Technology Transfer, **NIH** with inert samples of the **Licensed Products** or their packaging for educational and display purposes only.
4. This **Agreement** shall become effective on the date when the last party to sign has executed this **Agreement**, unless the provisions of Paragraph 25 are not fulfilled, and shall expire \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (X) years from this effective date, unless previously terminated under the terms of Paragraphs 16 or 17.
5. As part of the **Licensee's** performance under this **Agreement**, the **Licensee** agrees to make the **Licensed Products** available to the public within \_\_\_\_\_\_\_\_ (X) months from the effective date of this **Agreement**.
6. The **Licensee** agrees to retain control over the **Materials** and the **Licensed Products**, and not to distribute them to third parties without the prior written consent of the **IC** except as provided in Paragraph 3.
7. This **Agreement** does not preclude the **IC** from distributing the **Materials** or the **Licensed Products** to third parties for research or commercial purposes.
8. By this **Agreement**, the **IC** grants no patent rights expressly or by implication to any anticipated or pending **IC** patent applications or issued patents.
9. NO WARRANTIES, EXPRESS OR IMPLIED, ARE OFFERED AS TO THE MERCHANTABILITY OR FITNESS FOR ANY PURPOSE OF THE **MATERIALS** PROVIDED TO THE **LICENSEE** UNDER THIS **AGREEMENT**, OR THAT THE **MATERIALS** OR THE **LICENSED PRODUCTS** MAY BE EXPLOITED WITHOUT INFRINGING THE PATENT RIGHTS OF ANY THIRD PARTIES. The **Licensee** accepts license rights to the **Materials** and the **Licensed Products** “as is”, and the **IC** does not offer any guarantee of any kind.
10. **Licensee** agrees to indemnify and hold harmless the **Government** from any claims, costs, damages, or losses that may arise from or through the **Licensee's** use of the **Materials** or the **Licensed Products**. The **Licensee** further agrees that it shall not by its action bring the **Government** into any lawsuit involving the **Materials** or the **Licensed Products**.
11. The **Licensee** agrees in its use of the **Materials** or the **Licensed Products** to comply with all applicable statutes, regulations, and guidelines, including **NIH** and **HHS** regulations and guidelines. The **Licensee** agrees not to use the **Materials** or the **Licensed Products** for research involving human subjects or clinical trials in the United States without complying with [21 C.F.R. Part 50](http://www.access.gpo.gov/nara/cfr/waisidx_02/21cfr50_02.html) and [45 C.F.R. Part 46](http://www.access.gpo.gov/nara/cfr/waisidx_03/45cfr46_03.html). The **Licensee** agrees not to use the **Materials** or the **Licensed Products** for research involving human subjects or clinical trials outside of the United States without notifying the **IC**, in writing, of such research or trials and complying with the applicable regulations of the appropriate national control authorities. Written notification to the **IC** of research involving human subjects or clinical trials outside of the United States shall be given no later than sixty (60) days prior to commencement of such research or trials.
12. The **Licensee** may terminate this **Agreement** upon thirty (30) days written notice to the **IC** but only after sixty (60) days from the effective date of this **Agreement**.
13. The **IC** may terminate this **Agreement** if the **Licensee** is in default in the performance of any material obligation under this **Agreement**, and if the default has not been remedied within ninety (90) days after the date of written notice by the **IC** of the default.
14. Within thirty (30) days of the termination or expiration of this **Agreement**, the **Licensee** agrees to return all **Materials** and the **Licensed Products** to the **IC** or provide the **IC** with written certification of their destruction.
15. Within ninety (90) days of termination or expiration of this **Agreement**, the **Licensee** agrees to submit a final report to the **IC**, and to submit to the **IC** payment of any royalties due. The **Licensee** may not be granted additional **IC** licenses if this final reporting requirement is not fulfilled.
16. The **Licensee** is encouraged to publish the results of its research projects using the **Materials** or the **Licensed Products**. In all oral presentations or written publications concerning the **Materials** or the **Licensed Products**, the **Licensee** shall acknowledge the contribution of Dr. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ at the **IC** supplying the **Materials**, unless requested otherwise by the **IC** or Dr. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_.
17. This **Agreement** shall be construed in accordance with U.S. Federal law, as interpreted and applied by the U.S. Federal courts in the District of Columbia. Federal law and regulations shall preempt any conflicting or inconsistent provisions in this **Agreement**. The **Licensee** agrees to be subject to the jurisdiction of U.S. courts.
18. This **Agreement** constitutes the entire understanding of the **IC** and the **Licensee** and supersedes all prior agreements and understandings with respect to the **Materials** or the **Licensed Products**.
19. The provisions of this **Agreement** are severable, and in the event that any provision of the **Agreement** shall be determined to be invalid or unenforceable under any controlling body of law, the invalidity or unenforceability of any provision of this **Agreement**, shall not in any way affect the validity or enforceability of the remaining provisions of this **Agreement**.
20. Paragraphs 4, 13, 14, 18, 19, 20 and 24 of this **Agreement** shall survive termination or expiration of this **Agreement**.
21. The terms and conditions of this **Agreement** shall, at the **IC’s** sole option, be considered by the **IC** to be withdrawnfrom the **Licensee’s** consideration and the terms and conditions of this **Agreement**,and the **Agreement** itself to be null and void,unless this **Agreement** is executedby the **Licensee** and a fully executed original is received by the **IC** within sixty (60) days from the date of the **IC** signature found at the Signature Page.

**SIGNATURES BEGIN ON NEXT PAGE**

**THE IC BIOLOGICAL MATERIALS LICENSE AGREEMENT**

**SIGNATURE PAGE**

In Witness Whereof, the parties have executed this **Agreement** on the dates set forth below. Any communication or notice to be given shall be forwarded to the respective addresses listed below.

For the **IC**:

\_\_\_\_\_\_\_\_\_**DRAFT**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Name Date

Title

Office

National Institutes of Health

Mailing Address or E-mail Address for **Agreement** notices and reports:

License Compliance and Administration

Monitoring & Enforcement

Office of Technology Transfer

National Institutes of Health

6011 Executive Boulevard, Suite 325

Rockville, Maryland  20852-3804 U.S.A.

E-mail: LicenseNotices\_Reports@mail.nih.gov

For the **Licensee** (Upon, information and belief, the undersigned expressly certifies or affirms that the contents of any statements of the **Licensee** made or referred to in this document are truthful and accurate.):

by:

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ DRAFT**

Signature of Authorized Official Date

Printed Name

Title

1. Official and Mailing Address for **Agreement** notices:

Name

Title

Mailing Address

Email Address:

Phone:

Fax:

1. Official and Mailing Address for Financial notices (the **Licensee’s** contact person for royalty payments)

Name

Title

Mailing Address:

Email Address:

Phone:

Fax:

Any false or misleading statements made, presented, or submitted to the **Government**, including any relevant omissions, under this **Agreement** and during the course of negotiation of this **Agreement** are subject to all applicable civil and criminal statutes including Federal statutes [31 U.S.C. §§3801‑3812](http://frwebgate.access.gpo.gov/cgi-bin/usc.cgi?ACTION=BROWSE&TITLE=31USCSIII&PDFS=YES) (civil liability) and [18 U.S.C. §1001](http://frwebgate.access.gpo.gov/cgi-bin/usc.cgi?ACTION=RETRIEVE&FILE=$$xa$$busc18.wais&start=1925859&SIZE=10370&TYPE=TEXT) (criminal liability including fine(s) and/or imprisonment).

APPENDIX A – SHIPPING INFORMATION

**The Licensee’s Shipping Contact: information or questions regarding shipping should be directed to the Licensee’s Shipping Contact at:**

Shipping Contact’s Name Title

Phone: () Fax: () E-mail:

**Shipping Address: Name & Address to which Materials should be shipped (please be specific):**

Company Name & Department

Address:

**The Licensee’s** shipping carrier and account number to be used for shipping purposes:

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Appendix B – Example Royalty Report

**Required royalty report information includes:**

• License reference number (L-XXX-200X/0)

• Reporting period

• Catalog number and units sold of each Licensed Product (domestic and foreign)

• Gross Sales per catalog number per country

• Total Gross Sales

• Itemized deductions from Gross Sales

• Total Net Sales

• Earned Royalty Rate and associated calculations

• Gross Earned Royalty

• Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made

• Net Earned Royalty due

**Example**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Catalog Number** | **Product Name** | **Country** | **Units Sold** | **Gross Sales (US$)** |
| 1 | A | US | 250 | 62,500 |
| 1 | A | UK | 32 | 16,500 |
| 1 | A | France | 25 | 15,625 |
| 2 | B | US | 0 | 0 |
| 3 | C | US | 57 | 57,125 |
| 4 | D | US | 12 | 1,500 |

Total Gross Sales 153,250

Less Deductions:

Freight 3,000

Returns 7,000

Total Net Sales 143,250

Royalty Rate 8%

Royalty Due 11,460

Less Creditable Payments 10,000

**Net Royalty Due 1,460**

Appendix C – Royalty Payment Options

**The License Number MUST appear on payments, reports and correspondence**.

**Credit and Debit Card Payments**

**Credit and debit card payments can be submitted for amounts up to $29,999. Submit your payment through the U.S. Treasury web site located at:** [**https://www.pay.gov/public/form/start/28680443**](https://www.pay.gov/public/form/start/28680443)**.**

**Automated Clearing House (ACH) for payments through U.S. banks only**

The **IC** encourages its licensees to submit electronic funds transfer payments through the Automated Clearing House (ACH). Submit your ACH payment through the U.S. Treasury web site located at: <https://www.pay.gov/public/form/start/28680443>**.** Please note that the IC “only” accepts ACH payments through this U.S. Treasury web site.

**Electronic Funds Wire Transfers**

The following account information is provided for wire payments. In order to process payment via Electronic Funds Wire Transfer sender MUST supply the following information within the transmission:

Drawn on a **U.S. bank account** via FEDWIRE should be sent directly to the following account:

Beneficiary Account: Federal Reserve Bank of New York or TREAS NYC

Bank: Federal Reserve Bank of New York

ABA# 021030004

Account Number: 750800**31**

Bank Address: 33 Liberty Street, New York, NY 10045

 Payment Details: License Number (L-XXX-XXXX)

 Name of the Licensee

 Drawn on a **foreign bank account** should be sent directly to the following account. Payment must be sent in **U.S. Dollars (USD)** using the following instructions:

 Beneficiary Account: Federal Reserve Bank of New York/ITS or FRBNY/ITS

 Bank: Citibank N.A. (New York)

 SWIFT Code: CITIUS33

 Account Number: 36838868

 Bank Address: 388 Greenwich Street, New York, NY 10013

 Payment Details (Line 70): **NIH** 75080031

 License Number (L-XXX-XXXX)

 Name of the Licensee

 Detail of Charges (line 71a): Charge Our

**Checks**

All checks should be made payable to “NIH Patent Licensing”

Checks drawn on a **U.S. bank account** and sent by US Postal Service should be sent directly to the following address:

National Institutes of Health

P.O. Box 979071

St. Louis, MO 63197-9000

Checks drawn on a U.S. bank account and sent by **overnight or courier** should be sent to the following address:

US Bank

Government Lockbox SL-MO-C2GL

1005 Convention Plaza

St. Louis, MO 63101

Phone: 314-418-4087

Checks drawn on a **foreign bank account** should be sent directly to the following address:

National Institutes of Health

Office of Technology Transfer

License Compliance and Administration

Royalty Administration

6011 Executive Boulevard

Suite 325, MSC 7660

Rockville, Maryland 20852